Treatment

CURATED BY: Jon Falletta,
PA-C, CAQ-Psych
Recent advances have introduced treatment options, including VMAT2 inhibitors, for patients with tardive dyskinesia (TD), which help suppress symptoms, though they do not address the underlying causes....

Electroconvulsive Therapy: A Promising Alternative for Movement Disorders

Electroconvulsive therapy (ECT), traditionally used for psychiatric disorders, is increasingly recognized for its efficacy in managing movement disorders, even without...
CURATED BY:
Angela C. Combs,
MN, ARNP, PMHNP-BC

Understanding Extrapyramidal System Dysfunction: Causes, Symptoms, and Advances in Treatment

The extrapyramidal system, a complex neural network that coordinates involuntary movements and postural adjustments, plays a vital role in maintaining...
CURATED BY:
Angela C. Combs,
MN, ARNP, PMHNP-BC

Deutetrabenazine Proven Effective and Safe for Long-Term Tardive Dyskinesia Management

Tardive dyskinesia (TD), often associated with dopamine receptor antagonist (DRA) use, affects individuals with psychotic or mood disorders. This study...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

VMAT1 and VMAT2 Key to Neurotransmitter Packing, Opening Avenues for Neurological Treatments

The vesicular monoamine transporters, VMAT1 and VMAT2, play crucial roles in packing neurotransmitters into synaptic vesicles, essential for neurotransmission and...
CURATED BY:
Angela C. Combs,
MN, ARNP, PMHNP-BC

Managing VMAT2 Inhibitor Side Effects for Tardive Dyskinesia

At the 2021 Psych Congress Regionals, Dr. Rakesh Jain discussed the symptoms of tardive dyskinesia and provided updates on treatments,...
CURATED BY:
Jeremy Schreiber,
MSN, PMHNP-BC

Promising Therapies for Tardive Dyskinesia: Efficacy and Safety of Valbenazine and Deutetrabenazine

Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary movements, often caused by dopamine receptor antagonists. Vesicular monoamine transporter...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Share